Infliximab (Remicade®, Inflectra®, Renflexis®, Avsola™)

Infliximab (Remicade, Inflectra, Renflexis, Avsola) is covered for specified FDA‑approved and compendial off‑label indications (e.g., Crohn’s disease, ulcerative colitis, RA, PsA, plaque psoriasis, ankylosing spondylitis, uveitis, Behçet’s, GVHD, hidradenitis suppurativa, juvenile idiopathic arthritis, sarcoidosis, pyoderma gangrenosum, scleritis, Still’s disease, other SpA subtypes, and immunotherapy‑related toxicities except hepatitis) and is not covered when indication‑specific criteria are not met. Coverage requires documentation of diagnosis, indication‑specific prior therapy trials/intolerance or contraindications, prescriber or specialist consultation as specified, age limits where noted (commonly ≥6 or ≥18), adherence to dosing/frequency limits, and documented response for reauthorization.

"Crohn's disease"

Sign up to see full coverage criteria, indications, and limitations.